• Vaccine Name: Cancer DNA Vaccine pSURV encoding Survivin
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011365
• Type: DNA vaccine
• Status: Research
• Survivin gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• CD40 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000019
• Immunization Route: Intradermal injection (i.d.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: C57BL/6 mice were anesthetized with isoflurane and injected intradermally with 40 μg (40 μl of PBS) of plasmid DNA at two sites (20 μg each) near the base of the tail using a 29-gauge insulin-grade syringe. Mice were immunized two times either at days −21 and −7 (early setting) or at days +10 and +17 (late setting) with respect to tumor challenge, referred as day 0 (Lladser et al., 2010).
• Immune Response: Intradermal DNA EP of mice with a human survivin encoding plasmid generated CD8+ cytotoxic T lymphocyte (CTL) responses cross-reactive with the mouse epitope surv(20-28), as determined by intracellular IFN-gamma staining, suggesting that self-tolerance has been broken. Survivin-specific CTLs displayed an activated effector phenotype as determined by CD44 and CD107 up-regulation. Vaccinated mice displayed specific cytotoxic activity against B16 and peptide-pulsed RMA-S cells in vitro as well as against surv(20-28) peptide-pulsed target cells in vivo (Lladser et al., 2010).
• Challenge Protocol: Mice were challenged with a lethal dose of syngeneic B16 melanoma cells (Lladser et al., 2010).
• Efficacy: Intradermal EP with a survivin DNA vaccine suppressed angiogenesis in vivo and elicited protection against highly aggressive syngeneic B16 melanoma tumor challenge (Lladser et al., 2010).